11 different studies have been conducted in Chagas Disease for 4 different Clients. LAT was audited by Sponsors and underwent Inspections by the Competent Authorities in different countires.

• LAT's services for regulatory activities and monitoring were contracted for a Phase I study with 36 subjects at a site in Argentina.
• LAT was awarded a full service contract for a Pharmacokinectic Drug-Drug interaction
  study of 2 drugs for Chagas Disease on Healthy Volunteers.
• LAT was contracted to collaborate in a Phase II study conducted in Bolivia, where 260
  adults with Chronic Chagas Disease were enrolled.
• LAT was awarded a full service pediatric study for Chagas Disease. 81 patients were
  enrolled, at 5 sites. The results of the study were included in the FDA application.
• LAT was contracted by a Biotech Company to conduct 2 retrospective Phase IV studies.
• LAT was awarded a full service contract by a Large Pharma Company to run the largest
  pediatric study on Chagas Disease. The study was conducted in Argentina, Bolivia and Colombia, 330 children were enrolled.
• LAT's monitoring, data management and statistical analysis were contracted for a Phase III study for more than 900 patients with Chronic Indeterminate Chagas.

LAT was selected as partner of choice by a leading French biotech in probiotics. As a result of a successful synergy, 3 studies have been executed so far in pediatric and adult population.

In the main study, 316 children under 5 years old with acute diarrhea were enrolled in 8 sites in Argentina.

LAT was awarded a transfer study from a Large WW CRO on RA, which was condacted in Argentina, Mexico and Brazil.

Despite of the complicated landscape a study transfer represents, LAT was able to duplicate the number of sites and reach the target population of 2200 enrolled patient, in a year.

A key factor for the success of enrollment, is the close relationship LAT keeps with KOL and Investigative Sites, growing a network of high performing sites. LAT was able to enroll 1281 subject in 5 months at 39 Investigative Sites.

A local Argentine laboratory contracted LAT as a consultant for clinical studies to test and proved a spray for alopecia.

LAT was finally contracted to perform all the clinical development. Based on the results and the methodology of the clinical studies, the client was able to register their product in many countries, including European Community’s countries.